↑ 疾患リストへ ← 戻る

 17. 多系統萎縮症 [臨床試験数:51,薬物数:85(DrugBank:41),標的遺伝子数:57,標的パスウェイ数:19] 

Searched query = "Multiple system atrophy", "Olivopontocerebellar atrophy", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03753763September 9, 201928 October 2019Safinamide for Multiple System Atrophy (MSA)12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSAMultiple System AtrophyDrug: Safinamide Methanesulfonate;Drug: Safinamide Methanesulfonate matching placeboZambon SpARecruiting30 Years80 YearsAll48Phase 2Italy;Spain
2NCT04004819August 15, 201930 September 2019Rituximab for Multiple System AtrphyRituximab Therapy for the Patients With Multiple Syetem AtrophyMultiple System AtrophyDrug: RituximabFirst Affiliated Hospital of Fujian Medical UniversityRecruiting18 Years80 YearsAll50Phase 2China
3NCT03952806July 29, 201911 November 2019Study of BHV-3241 in Subjects With Multiple System AtrophyA Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System AtrophyMultiple System AtrophyDrug: Verdiperstat;Drug: PlaceboBiohaven Pharmaceuticals, Inc.Recruiting40 Years75 YearsAll250Phase 3United States;Austria;France;Germany;Italy;United Kingdom
4JPRN-UMIN0000369522019/06/0416 July 2019A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.18F-FDOPA, 11C-Raclopride PETNagoya City Rehabilitation AgencyRecruiting20years-oldNot applicableMale and Female150Not applicableJapan
5NCT03901638April 2, 201915 April 2019Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System AtrophyGut Microbiota Alteration and Improvement of Ataxia in Patients of Multiple System Atrophy Treating With Tllsh2910 - a Randomized, Placebo-controlled, Double-blinded, Cross-over, Single-center Clinical TrialAtaxia, Cerebellar;Multiple System AtrophyDrug: Tllsh2910;Drug: PlaceboNational Taiwan University HospitalRecruiting18 Years80 YearsAll60Phase 3Taiwan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03589976September 1, 201814 October 2019A Futility Trial of Sirolimus in Multiple System AtrophyA Single Center Randomized,Double Blind, Placebo-controlled Futility Trial to Determine if Sirolimus is of Sufficient Promise to Slow the Progression of Multiple System AtrophyMultiple System AtrophyDrug: Sirolimus 2 MG;Other: PlaceboNYU Langone HealthNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting30 Years80 YearsAll56Phase 2United States
7NCT03403309May 2, 201815 July 2019Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical TrialInosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial (IMPROVE MSA Study)Multiple System AtrophyDrug: 1) Inosine 5'-monophosphate;Drug: PlaceboYonsei UniversityNot recruiting19 Years75 YearsAll43Phase 2Korea, Republic of
8NCT03265444April 13, 201811 June 2018Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System AtrophyA Phase 1 Study to Evaluate the Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Multiple System AtrophyMultiple System AtrophyBiological: CS10BR05Corestem, Inc.Recruiting30 Years75 YearsAll9Phase 1Korea, Republic of
9NCT03446807April 201811 June 2018Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismSafety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismParkinson Disease;Multiple System Atrophy;Progressive Supranuclear PalsyDrug: Droxidopa;Drug: Placebo Oral TabletLoma Linda UniversityH. Lundbeck A/SNot recruiting50 YearsN/AAll32Phase 2United States
10NCT03174938May 15, 201711 June 2018The Swedish BioFINDER 2 StudyThe Swedish BioFINDER 2 StudyDementia;Alzheimer Disease;Parkinson Disease;Lewy Body Disease;Parkinson-Dementia Syndrome;Frontotemporal Degeneration;Semantic Dementia;Progressive Nonfluent Aphasia;Progressive Supranuclear Palsy;Corticobasal Degeneration;Multiple System Atrophy;Mild Cognitive ImpairmentDiagnostic Test: Flutemetamol F18 Injection;Diagnostic Test: [18F]-RO6958948;Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau;Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and PtauSkane University HospitalLund UniversityRecruiting20 Years100 YearsAll1505N/ASweden
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02897063September 201625 February 2019Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureThe Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2Autonomic Failure;Pure Autonomic Failure;Multiple System Atrophy;Parkinson Disease;Orthostatic HypotensionDrug: Droxidopa;Drug: Midodrine;Drug: PlaceboVanderbilt University Medical CenterRecruiting40 Years80 YearsAll34Phase 1United States
12NCT02705755May 20167 October 2019TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic HypotensionNeurogenic Orthostatic Hypotension;Multiple System Atrophy (MSA) With Orthostatic Hypotension;Pure Autonomic Failure;Parkinson Disease;Hypotension, Orthostatic;Orthostatic Hypotension;Pure Autonomic Failure With Orthostatic Hypotension;Parkinson Disease With Orthostatic HypotensionDrug: TD-9855;Drug: PlaceboTheravance BiopharmaNot recruiting40 YearsN/AAll34Phase 2United States
13NCT02726711April 201625 February 2019Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in AutonomicReduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2Multiple System Atrophy;Orthostatic Hypotension;Supine HypertensionDrug: Trimethaphan;Drug: PlaceboVanderbilt UniversityRecruiting40 Years80 YearsAll32Phase 1United States
14NCT02994719March 1, 201618 December 2018Gait Analysis in Neurological DiseaseGait Pattern Analysis in Neurological DiseaseParkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, FrontalDrug: Anti-Parkinson medication;Device: Deep Brain StimulationBeth Israel Deaconess Medical CenterRecruiting18 Years85 YearsAll110N/AUnited States
15NCT02591173February 201626 August 2019Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic FailureBlood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic FailureAutonomic Nervous System Disorders;Pure Autonomic Failure;Shy-Drager Syndrome;Orthostatic Hypotension, DysautonomicDrug: Angiotensin-(1-7);Drug: SalineVanderbilt University Medical CenterRecruiting18 Years80 YearsAll22Early Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02388295April 27, 201516 December 2017AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA PatientsA 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System AtrophyMultiple System Atrophy, MSADrug: AZD3241;Drug: PlaceboAstraZenecaNot recruiting30 Years80 YearsAll59Phase 2United States;Austria;Finland;France;Italy;Sweden;United Kingdom
17EUCTR2014-004902-13-GB09/04/20157 December 2015Study to assess the effect of AZD3241 in Multiple System AtrophyA 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System AtrophyMultiple system atrophy (MSA)
MedDRA version: 18.1 Level: PT Classification code 10064060 Term: Multiple system atrophy System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AZD3241 100mg
Product Code: AZD3241
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Not available
CAS Number: 890655-80-8
Current Sponsor code: AZD3241
Other descriptive name: IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: AZD3241 300mg
Product Code: AZD3241
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Not available
CAS Number: 890655-80-8
Current Sponsor code: AZD3241
Other descriptive name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
AstraZeneca ABAuthorisedFemale: yes
Male: yes
64United States;Finland;United Kingdom;Sweden
18NCT02429557April 201525 February 2019Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic FailureHemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic FailureOrthostatic Hypotension;Pure Autonomic Failure;Multiple System Atrophy;Autonomic FailureOther: Abdominal compression;Other: Sham abdominal compression;Drug: Placebo pill;Drug: midodrineVanderbilt UniversityRecruiting18 Years80 YearsAll20Phase 1United States
19NCT02270489December 11, 201416 December 2017Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSAA Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System AtrophyMultiple System Atrophy;Neurodegenerative DiseasesBiological: AFFITOPE® PD01A + Adjuvant;Biological: AFFITOPE® PD03A + Adjuvant;Biological: Adjuvant without active componentAffiris AGUniversity Hospital, Bordeaux;Institut National de la Santé Et de la Recherche Médicale, France;Forschungszentrum Juelich;University Hospital, ToulouseNot recruiting30 Years75 YearsAll30Phase 1France
20NCT02149901October 201415 April 2019Water and Sudafed in Autonomic FailureEffect of Drinking Water on the Pressor Response to Pseudoephedrine in Patients With Autonomic FailureShy-Drager Syndrome;Multiple System AtrophyDrug: Pseudoephedrine + 480 ml water;Drug: Pseudoephedrine + 50 ml water;Other: Placebo + 480 ml water (optional);Other: Placebo + 50 ml water (optional)Vanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI);National Center for Advancing Translational Science (NCATS)Not recruiting18 Years80 YearsAll35Early Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21EUCTR2012-005539-10-DE29/04/20142 October 2017Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin InvestigationChronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury.
MedDRA version: 18.1 Level: PT Classification code 10039424 Term: Salivary hypersecretion System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Xeomin
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: NT 101
CAS Number: 93384-43-1
Current Sponsor code: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Powder for solution for injection
Route of administration of the placebo: Intraglandular use
Trade Name: Xeomin
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: NT 101
CAS Number: 93384-43-1
Current Sponsor code: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 50-
Pharmaceutical form of the placebo: Powder for solution for injection
Route of administration of the placebo: Intraglandular use
Merz Pharmaceuticals GmbHNot RecruitingFemale: yes
Male: yes
180Phase 3United States;Poland;Germany
22NCT02064166February 20143 December 2018Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System AtrophyParkinson Disease;Multiple System AtrophyDrug: Intranasal InsulinPeter NovakNot recruiting18 YearsN/AAll15Phase 2United States
23NCT02071459February 201416 December 2017Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSAEvaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus PlaceboMultiple System AtrophyDrug: L-Threo DOPS;Drug: placeboUniversity Hospital, ToulouseRecruiting30 Years80 YearsAll108Phase 2/Phase 3France
24EUCTR2012-000928-18-DE21/11/20135 December 2016Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA) - Progression Rate of MSA under EGCG Supplementation as anti-Aggregation-ApproachProgression of patients with Multiple System Atrophy (MSA);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Sunphenon EGCg
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: EGCG
CAS Number: 989-51-5
Current Sponsor code: EGCG
Other descriptive name: GREEN TEA LEAF
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 800-1200
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the placebo: Oral use
Hospital of the Ludwig-Maximilians-University of MunichNot RecruitingFemale: yes
Male: yes
86Phase 3Germany
25JPRN-UMIN0000111112013/07/162 April 2019Spinal blood flow and metabolism in neurological diseasesmotor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophyPET scan study with 11C-flumazenil
PET scan study with 18F- FDG
PET scan study with 15O-H2O
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesRecruiting20years-oldNot applicableMale and Female70Not applicableJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26JPRN-UMIN0000107122013/05/202 April 2019Ubiquinol for patients with multiple system atrophyPatients with multiple system atrophyPatients with administration of ubiquinolDepartment of Neurology, the University of Tokyo HospitalNot Recruiting30years-old80years-oldMale and Female1Not selectedJapan
27JPRN-UMIN0000089592012/11/012 April 2019Trial of molecular hydrogen water in Multiple system atrophy and Progressive supranuclear palsyMultiple system atrophy(MSA) Progressive supranuclear palsy (PSP)hydrogen water
pseudo-water (nitrogen filling water)
Juntendo University School of Medicine, Department of NeurologyNot Recruiting20years-old80years-oldMale and Female40Phase 1Japan
28NCT02315027October 201214 October 2019Mesenchymal Stem Cell Therapy in Multiple System AtrophyIntrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural HistoryMSABiological: autologous mesenchymal stem cellsMayo ClinicNot recruiting30 Years80 YearsAll30Phase 1United States
29NCT01577992December 201119 February 2015Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System AtrophyEvaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System AtrophyPain Threshold;Multiple System AtrophyDrug: Levodopa test;Procedure: determination of objective and subjective pain thresholdUniversity Hospital, ToulouseFondation de FranceNot recruiting50 Years80 YearsBoth42N/AFrance
30NCT01287221March 201119 October 2017Study of Rifampicin in Multiple System AtrophyDouble-Blind, Placebo-Controlled Study of Rifampicin in Multiple System AtrophyMultiple System AtrophyDrug: Rifampicin;Drug: placeboPhillip LowNational Institute of Neurological Disorders and Stroke (NINDS);Vanderbilt University;Rare Disease Research Network Autonomic ConsortiumNot recruiting30 Years80 YearsAll100Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT01292694March 20113 September 2018Contribution of Angiotensin II to Supine Hypertension in Autonomic FailureContribution of Angiotensin II to Supine Hypertension in Autonomic FailureHypertension;Pure Autonomic Failure;Multiple System AtrophyDrug: Losartan;Drug: Captopril;Drug: PlaceboVanderbilt UniversityNot recruiting18 Years85 YearsAll12Phase 1United States
32EUCTR2009-018157-23-GB30/11/201019 March 2012A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyA Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System AtrophyMultiple system atrophy
MedDRA version: 12.1 Level: LLT Classification code 10064060 Term: Multiple system atrophy
Product Name: AZD3241
Product Code: AZD3241
Pharmaceutical Form: Tablet
Current Sponsor code: AZD3241
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: AZD3241
Product Code: AZD3241
Pharmaceutical Form: Tablet
Current Sponsor code: AZD3241
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
AstraZeneca ABNot RecruitingFemale: yes
Male: yes
135Phase 2aUnited Kingdom;Spain;Austria
33NCT01119417May 201025 February 2019The Role of Endothelin in the Supine Hypertension of Autonomic FailureThe Role of Endothelin in the Supine Hypertension of Autonomic FailureHypertension;Pure Autonomic Failure;Multiple System AtrophyDrug: BQ123;Drug: Bq123;Drug: SalineVanderbilt UniversityRecruiting18 Years85 YearsAll12Phase 1United States
34NCT01136213April 201016 December 2017Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) StudyMorphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET StudyMultiple System AtrophyRadiation: PET (Positron Emission Tomography) Study;Other: Brain MRI (magnetic resonance imaging);Drug: Fluoxétine / PlaceboUniversity Hospital, BordeauxNot recruiting30 Years80 YearsAll53N/AFrance
35NCT01044693January 201019 October 2017Nebivolol in the Supine Hypertension of Autonomic FailureEffect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide BioactivityHypertension;Pure Autonomic Failure;Multiple System AtrophyDrug: Placebo;Drug: Nebivolol 5 mg;Drug: metoprolol tartrate 50 mg;Drug: Sildenafil25 mgVanderbilt UniversityForest LaboratoriesNot recruiting18 Years80 YearsAll20N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36EUCTR2009-014644-11-DE08/12/200922 October 2012A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)Multiple System Atrophy of the Parkinsonian Subtype
MedDRA version: 12.0 Level: PT Classification code 10064060 Term: Multiple system atrophy
Trade Name: AZILECT
Pharmaceutical Form: Tablet
INN or Proposed INN: Rasagiline
CAS Number: 161735-79-1
Current Sponsor code: TVP-1012
Other descriptive name: Rasagiline mesylate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Teva Pharmaceutical Industries LtdNot RecruitingFemale: yes
Male: yes
140Portugal;France;Hungary;Spain;Austria;Netherlands;Germany;United Kingdom;Italy
37NCT00997672October 200919 October 2017Lithium in Multiple System AtrophyA Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Tolerability of Lithium in Multiple System Atrophy.Multiple System AtrophyDrug: Lithium Carbonate;Drug: PlaceboFederico II UniversityNot recruiting18 Years80 YearsAll10Phase 2Italy
38NCT00758849September 200819 February 2015Fipamezole in Neurogenic Orthostatic HypotensionA Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients With Multiple System Atrophy or Parkinson's DiseaseSymptomatic Neurogenic Orthostatic Hypotension (NOH);Parkinson's Disease;Multiple System AtrophyDrug: Placebo;Drug: FipamezoleJuvantia Pharma LtdSanthera PharmaceuticalsNot recruiting30 Years80 YearsBoth24Phase 2France;Portugal
39NCT00750867June 200816 December 2017Treatment of Multiple System Atrophy Using Intravenous ImmunoglobulinsTreatment of Multiple System Atrophy Using Intravenous ImmunoglobulinsMultiple System AtrophyDrug: intravenous immunoglobulin (IVIg)University of Massachusetts, WorcesterNot recruiting18 YearsN/AAll9Phase 2United States
40NCT00822913June 200819 February 2015Botulinum A Toxin in Patients With Parkinson's DiseaseThe Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity.Parkinson's Disease;Multiple System Atrophy;Detrusor OveractivityDrug: Intravesical injection of Botulinum A toxinUniversity Of PerugiaUniversity of Roma La SapienzaRecruiting18 Years80 YearsBoth20Phase 4
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41EUCTR2007-004890-24-FR07/05/200819 March 2012A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHNA Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy or Parkinson’s Disease - FOEHNNeurogenic orthostatic hypotension in patients with multiple system atrophy or Parkinson's disease
MedDRA version: 9.1 Level: LLT Classification code 10013113 Term: Disease Parkinson's
MedDRA version: 9.1 Level: LLT Classification code 10064060 Term: Multiple system atrophy
Product Name: Fipamezole hydrochloride 90 mg oral disintegrating tablets
Product Code: JP-1730/F01
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: Fipamezole hydrochloride
CAS Number: 150586-72-4
Current Sponsor code: JP-1730
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 90-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Sublingual use
Product Name: Fipamezole hydrochloride 60 mg oral disintegrating tablets
Product Code: JP-1730/F02
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: Fipamezole hydrochloride
CAS Number: 150586-72-4
Current Sponsor code: JP-1730
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 60-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Sublingual use
Product Name: Fipamezole hydrochloride 30 mg oral disintegrating tablets
Product Code: JP-1730/F03
Pharmaceutical Form: Orodispersible tablet
INN or Proposed INN: Fipamezole hydrochloride
CAS Number: 150586-72-4
Current Sponsor code: JP-1730
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Pharmaceutical form of the placebo: Orodispersible tablet
Route of administration of the placebo: Sublingual use
Juvantia Pharma LtdAuthorisedFemale: yes
Male: yes
24Phase 2Portugal;France
42NCT00911365May 200819 February 2015Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System AtrophyA Double-blind Placebo-controlled Randomized Clinical Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System AtrophyMultiple System AtrophyBiological: autologous mesenchymal stem cells;Biological: normal salineYonsei UniversityNot recruitingN/A75 YearsBoth27Phase 2Korea, Republic of
43NCT01146548May 20087 April 2015Fluoxetine in Multiple System Atrophy PatientsAssessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized TrialMultiple System AtrophyDrug: FLUOXETINEUniversity Hospital, ToulouseClinical Research Center, ToulouseNot recruiting30 Years80 YearsBoth87Phase 2France
44EUCTR2007-004922-26-FR12/02/200819 March 2012Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétineEvaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétineatrophie multisystématisée
MedDRA version: 9.1 Level: LLT Classification code 10064060 Term: Multiple system atrophy
Trade Name: PROZAC
Pharmaceutical Form: Capsule*
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
CHU ToulouseAuthorisedFemale: yes
Male: yes
France
45NCT00738062January 200819 October 2017Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensionNeurogenic Orthostatic Hypotension;Non-Diabetic Autonomic Neuropathy;Multiple System Atrophy;Dopamine Beta Hydroxylase DeficiencyDrug: Droxidopa;Drug: PlaceboChelsea TherapeuticsNot recruiting18 YearsN/AAll103Phase 3United States;Australia;Canada;New Zealand
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT00547911October 200719 October 2017Augmenting Effects of L-DOPS With Carbidopa and EntacaponeL-Dihydroxyphenylserine (L-DOPS) for Norepinephrine Deficiency: Interactions With Carbidopa and EntacaponeParkinson Disease;Multiple System Atrophy;Autonomic Nervous System DiseasesDrug: Droxidopa;Drug: Carbidopa;Drug: EntacaponeNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting18 YearsN/AAll14Phase 1/Phase 2United States
47NCT00103597January 200519 February 2015Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System AtrophyEfficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System AtrophyParkinson's Disease;Multiple System Atrophy;Orthostatic HypotensionDrug: Fludrocortisone;Drug: Domperidone;Behavioral: Conservative Measures for Orthostatic HypotensionRoyal Brisbane and Women's HospitalNot recruiting40 Years95 YearsBoth50Phase 1Australia
48NCT00179023April 200312 March 2018The Autonomic Nervous System and ObesityThe Autonomic Nervous System and ObesityOBESITY;HYPERTENSION;PURE AUTONOMIC FAILURE;SHY-DRAGER SYNDROMEDrug: Trimethaphan;Drug: PseudoephedrineVanderbilt UniversityNot recruiting18 Years80 YearsAll128Phase 1United States
49NCT01044992May 200219 February 2015Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) StudyMotor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and Dopaminergic ChallengeMultisystemic AtrophyRadiation: H215O PET;Drug: LevodopaUniversity Hospital, ToulouseNot recruiting40 Years75 YearsBoth38N/AFrance
50NCT00211224April 200019 February 2015Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)Multiple System Atrophy;Progressive Supranuclear PalsyDrug: RiluzoleKing's College LondonAssistance Publique - Hôpitaux de Paris;University of Ulm;Aventis PharmaceuticalsNot recruiting30 Years80 YearsBoth800Phase 3United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT00004478March 199919 February 2015Droxidopa in Treating Patients With Neurogenic HypotensionStudy of Droxidopa in Patients With Neurologic HypotensionShy-Drager Syndrome;Orthostatic HypotensionDrug: droxidopaMount Sinai School of MedicineNot recruiting20 YearsN/ABothN/AUnited States

先頭へ